IO Biotech annual free cash flow
2021
2022
2023
2024
IO Biotech reported −$82.4M in free cash flow for fiscal 2024, a decrease of $10.3M from the previous fiscal year.
View full IO Biotech company overview| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2024 | 2024-12-31 | −$82.4M | −$10.3M | — | — |
| 2023 | 2023-12-31 | −$72.1M | −$11.6M | — | — |
| 2022 | 2022-12-31 | −$60.4M | −$19.6M | — | — |
| 2021 | 2021-12-31 | −$40.8M | — | — | — |
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q3 2025 | 2025-09-30 | −$18.5M | $2.3M | — | — |
| Q2 2025 | 2025-06-30 | −$19.8M | −$2.9M | — | — |
| Q1 2025 | 2025-03-31 | −$23.1M | $1.8M | — | — |
| Q4 2024 | 2024-12-31 | −$19.6M | $3.3M | — | — |
| Q3 2024 | 2024-09-30 | −$20.8M | −$4.8M | — | — |
| Q2 2024 | 2024-06-30 | −$17.0M | $1.3M | — | — |
| Q1 2024 | 2024-03-31 | −$24.9M | −$10.1M | — | — |
| Q4 2023 | 2023-12-31 | −$22.9M | −$10.0M | — | — |
| Q3 2023 | 2023-09-30 | −$16.0M | −$2.5M | — | — |
| Q2 2023 | 2023-06-30 | −$18.3M | −$5.2M | — | — |
| Q1 2023 | 2023-03-31 | −$14.8M | $6.1M | — | — |
| Q4 2022 | 2022-12-31 | −$12.9M | — | — | — |
| Q3 2022 | 2022-09-30 | −$13.5M | — | — | — |
| Q2 2022 | 2022-06-30 | −$13.1M | — | — | — |
| Q1 2022 | 2022-03-31 | −$21.0M | — | — | — |
IO Biotech's latest reported quarter, Q3 2025, generated −$18.5M in free cash flow, an increase of $2.3M year over year.
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review IO Biotech filings at SEC.gov ↗